Valion Bio, Inc. (VBIO)
NASDAQ: VBIO · Real-Time Price · USD
0.555
-0.022 (-3.88%)
At close: Jun 26, 2026, 4:00 PM EDT
0.530
-0.025 (-4.49%)
After-hours: Jun 26, 2026, 7:55 PM EDT
Company Description
Valion Bio, Inc. operates as a late-stage biopharmaceutical company.
Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome.
The company’s pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence.
In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026.
The company was incorporated in 2016 and is based in San Antonio, Texas.
Valion Bio, Inc.
| Country | United States |
| Founded | 2016 |
| IPO Date | Nov 11, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 52 |
| CEO | Michael Handley |
Contact Details
Address: 1305 E. Houston Street, Suite 311, Building 1 San Antonio, Texas 78205 United States | |
| Phone | 888 276 6888 |
| Website | valionbio.com |
Stock Details
| Ticker Symbol | VBIO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001787740 |
| ISIN Number | US8887053085 |
| Employer ID | 81-4016391 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael Kevin Handley | Chief Executive Officer and Director |
| Lisa G. Wolf | Chief Financial Officer and Principal Financial and Principal Accounting Officer |
| Melinda Lackey | General Counsel and Senior Vice President of Legal Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 18, 2026 | 8-K | Current Report |
| Jun 5, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 5, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 3, 2026 | 8-K | Current Report |
| May 14, 2026 | 10-Q | Quarterly Report |
| May 14, 2026 | 8-K | Current Report |
| May 8, 2026 | SCHEDULE 13G/A | Filing |
| May 4, 2026 | 8-K | Current Report |
| Apr 30, 2026 | ARS | Filing |
| Apr 30, 2026 | DEF 14A | Other definitive proxy statements |